1. Scrip
  2. >>R&D
  3. >>Clinical Trials

First Signs Of Efficacy From Biogen’s Tau-Targeting Antisense Drug

 
• By Andrew McConaghie

After showing an impressive 60% reduction in tau levels in the brain, Biogen’s Phase I study of BIIB080 has now demonstrated early signs of an impact on cognition and daily living for Alzheimer’s patients.

Biogen

Earlier this year, Biogen presented eye-catching results from its Alzheimer’s disease candidate BIIB080, which showed it produced ”unprecedented” reductions in the tau protein – and has now followed this with small but encouraging signs that this effect also helps to slow the disease’s progress.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.